Pancreatic Cancer Initial Detection Via Liquid Biopsy (PANCAID)

Karolinska University Hospital

Status: Invitation-only

Conditions: Chronic Pancreatitis; Individuals at Risk; IPMN, Pancreatic; Pancreatic Cancer

Treatments: Diagnostic Test: Liquid biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT06283576

PANCAID-00-08

Details and patient eligibility

About

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Suspicion of or elevated risk for pancreatic ductal adenocarcinoma (PDAC); intraductal papillary mucinous neoplasias (IPMN); individuals at risk (IAR) for pancreatic cancer

Exclusion criteria

• other malignant condition

Trial design

200 participants in 4 patient groups

Pancreatic cancer, early

Description:

Early pancreatic cancer, T1/T2 NoM0

Treatment:

Diagnostic Test: Liquid biopsy

IPMN

Treatment:

Diagnostic Test: Liquid biopsy

Pancreatic cancer, advanced

Description:

Advance pancreatic cancer T1-4, Nx, Mx

Treatment:

Diagnostic Test: Liquid biopsy

Healthy controls

Treatment:

Diagnostic Test: Liquid biopsy